Among 33 women with M1 BC and HER2-negative primary tumor, ≥1 HER2-positive CTC/7.5 mL were detected in 39.4%, (95%CI 24.7–56.3%, median 1.5 cells, range 1–42 cells). This evidence concerns the gene ERBB2 and breast cancer.